Key result
Each ng/mL increase in NGAL is linked to ~2% more adverse events after scheduled PCI.
Why the study?
To evaluate the prognostic value of different indicators as markers of adverse outcomes in patients with stable CHD after scheduled PCI.
Cohort (n=74)
In patients with stable coronary heart disease undergoing scheduled PCI, the NGAL level serves as a significant independent predictor of adverse cardiovascular events.
NGAL may aid post-PCI risk stratification in stable CHD; hypothesis-generating and should not yet change practice.
Objective. To study the prognostic value of different indicators as markers of adverse outcomes in patients with stable coronary heart disease (CHD) after scheduled percutaneous coronary interventions. Material and methods. The prospective study included 74 patients (58 females and 16 males) diagnosed with stable CHD who underwent a percutaneous coronary intervention (PCI). The average age of the patients was 65 (59;71) years. The endpoints analyzed after 16 (9; 22) months included general and cardiovascular death, non-fatal myocardial infarction, non-fatal acute cerebrovascular accident, hospitalization for decompensation of chronic heart failure (CHF), unstable angina, as well as an integrated endpoint combining all the adverse outcomes listed above. Results. The endpoints were analyzed after 16 (9; 22) months. The adverse outcomes structure was dominated by non-fatal acute cerebrovascular accidents — in 8 (29.6%) patients, hospitalization for CHF decompensation and restenosis of previously installed stents — in 7 (25.9%) patients each, and fatal outcome — in 5 (18.5%) patients. The multivariate Cox regression analysis showed that only the NGAL level was a significant independent predictor of adverse events: HR — 1.020, 95% CI 1.002—1.037, p=0.031. So, an increase in the NGAL level by 1 ng/mL increases the risk of an earlier outcome by 2%. Conclusion. The results obtained prove that only the NGAL level out of all studied indicators has an unfavorable impact on the prognosis. An increase in the NGAL level by 1 ng/mL increases the risk of an earlier outcome by 2%.
No takes yet. Share an insight, caveat, or question.
Svarovskaya et al. (2024) conducted a cohort in Stable coronary heart disease after scheduled percutaneous coronary interventions (n=74). NGAL level was evaluated on Adverse events (general and cardiovascular death, non-fatal myocardial infarction, non-fatal acute cerebrovascular accident, hospitalization for CHF decompensation, unstable angina) (HR 1.020, 95% CI 1.002-1.037, p=0.031). An increase in NGAL level by 1 ng/mL was a significant independent predictor of adverse events after scheduled PCI (HR 1.020; 95% CI 1.002-1.037; p=0.031).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: